原创力文档- 1、原创力文档（book118）网站文档一经付费（服务费），不意味着购买了该文档的版权，仅供个人/单位学习、研究之用，不得用于商业用途，未经授权，严禁复制、发行、汇编、翻译或者网络传播等，侵权必究。。
- 2、本站所有内容均由合作方或网友上传，本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺！文档内容仅供研究参考，付费前请自行鉴别。如您付费，意味着您自己接受本站规则且自行承担风险，本站不退款、不进行额外附加服务；查看《如何避免下载的几个坑》。如果您已付费下载过本站文档，您可以点击 这里二次下载。
- 3、如文档侵犯商业秘密、侵犯著作权、侵犯人身权等，请点击“版权申诉”（推荐），也可以打举报电话：400-050-0827(电话支持时间：9:00-18:30)。
- 4、该文档为VIP文档，如果想要下载，成为VIP会员后，下载免费。
- 5、成为VIP后，下载本文档将扣除1次下载权益。下载后，不支持退款、换文档。如有疑问请联系我们。
- 6、成为VIP后，您将拥有八大权益，权益包括：VIP文档下载权益、阅读免打扰、文档格式转换、高级专利检索、专属身份标志、高级客服、多端互通、版权登记。
- 7、VIP文档为合作方或网友上传，每下载1次， 网站将根据用户上传文档的质量评分、类型等，对文档贡献者给予高额补贴、流量扶持。如果你也想贡献VIP文档。上传文档
查看更多
* Slide 9 The Andersson study is a prospective phase III, multicenter, randomized trial that was designed to evaluate the 有效性 and safety of NVB i.v. plus 曲妥珠单抗 as first-line regimen in patients with HER2 阳性. Patients were randomized to receive either NVB D1, D8 + 曲妥珠单抗 or 多西他赛 D1 plus 曲妥珠单抗 every three weeks. Patients population was well balanced between both arms. Median number of cycles received by patients was higher for those treated with NVB plus 曲妥珠单抗 (10.5 versus 8). Concerning the 有效性 results, OS, OR and TTP were better with 曲妥珠单抗 in combination with NVB. Furthermore, difference for TTF was clinically significant for NVB arm. Based on this efficay results, the author concluded that NVB combined with 曲妥珠单抗 should be considered a potentially better first line alternative. * Slide 10 Significantly more grade 3-4 白细胞下降, 发热性粒缺, 感染, 发热, neuropathy, 指甲异常 and 水潴留 were reported with 多西他赛. 20% of patients treated with 多西他赛 were discontinued due to 毒性 versus 6.5% of patients treated with NVB. * * * * 结论与启示： 赫赛汀?治疗进展后持续使用长期获益 一线治疗7年 OS率为 17% （n= 220) 当赫赛汀? 持续治疗到疾病进展，OS率显著提高 (12.3% vs. 5.4%; P0.0001) 当赫赛汀? 持续治疗到疾病进展，中位OS显著提高 (3.1 vs. 1.45 year 法国观察研究长期随访资料为赫赛汀?治疗进展后使用取得长期获益增添了证据 617 General Poster Session (Board #11C), Mon, 1:00 PM-5:00 PM Long-term survival in patients with HER2-positive metastatic breast cancer treated with trastuzumab as first-line therapy: Seven-year follow-up of the French Observational Hermine Study. E. Antoine, F. Dalenc, C. Hebert, P. Rivera, G. Romieu, N. Varoqueaux, J. P. Guastalla, M. Namer; Clinique Hartmann, Neuilly-sur-Seine, France; Institut Claudius Regaud, Toulouse, France; Centre Antoine-Lacassagne, Nice, France; CHU Toulouse Rangueil, Toulouse, France; CRLC Val d’Aurelle, Montpellier, France; Roche, Neuilly-sur-Seine, France; Centre Léon Bérard, Lyon, France Background: The Hermine study observed the use of trastuzumab (TZ) in HER2-positive metastatic breast cancer (MBC) in routine practice (in first (1st)-, second-, or third-li
文档评论（0）